Today's New York Times features efforts to introduce pneumococcal conjugate vaccine in developing countries, where it has the potential to combat life-threatening respiratory disease. Importantly, the article notes progress in putting together the pledges for a pilot application of the Advance Market Commitment to stimulate development and manufacture of pneumo vaccine that would be appropriate for use in African and Asian countries: $1 billion of the estimated $1.5 billion required, with the notable absence to date of pledges from the US and France.
Disclaimer
CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise.
CGD is a nonpartisan, independent organization and does not take institutional positions.
Topics
